PATENT CLAIM ANALYSIS

Application Number: 16060714
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "274000"]

Abstract:
The present invention provides a modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels for use in the prophylaxis or treatment of pain. Modulators for use in the prophylaxis or treatment of pain include compounds of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof and/or derivative thereof: (I).

Claim (Index 39):
The method or according to claim  1 , wherein the modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 is a compound selected from the group consisting of:\n 5,5-dimethyl-3-[2-[[3-methyl-3-(trifluoromethyl)-1H-isobenzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione (enantiomer 1); 5,5-dimethyl-3-[2-[[3-methyl-3-(trifluoromethyl)-1H-isobenzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione (enantiomer 2); (5R)-3-[6-[(3,3-dimethyl-1H-isobenzofuran-5-yl)oxy]-3-pyridyl]-5-ethyl-5-methyl-imidazolidine-2,4-dione; 3-[6-[(3-tert-butyl-1,3-dihydroisobenzofuran-5-yl)oxy]-3-pyridyl]-5,5-dimethyl-imidazolidine-2,4-dione (enantiomer 1); 3-[6-[(3-tert-butyl-1,3-dihydroisobenzofuran-5-yl)oxy]-3-pyridyl]-5,5-dimethyl-imidazolidine-2,4-dione (enantiomer 2); 5,5-dimethyl-3-[6-[[3-methyl-3-(trifluoromethyl)-1H-isobenzofuran-5-yl]oxy]-3-pyridyl]imidazolidine-2,4-dione (enantiomer 1); 5,5-dimethyl-3-[6-[[3-methyl-3-(trifluoromethyl)-1H-isobenzofuran-5-yl]oxy]-3-pyridyl]imidazolidine-2,4-dione (enantiomer 2); 5,5-dimethyl-3-(6-spiro[1H-isobenzofuran-3,1\u2032-cyclobutane]-5-yloxy-3-pyridyl)imidazolidine-2,4-dione; (5R)-3-[6-[(3,3-dimethyl-1H-isobenzofuran-5-yl)oxy]-3-pyridyl]-5-ethyl-imidazolidine-2,4-dione; (5R)-5-ethyl-3-[6-[[3-methyl-3-(trifluoromethyl)-1H-isobenzofuran-5-yl]oxy]-3-pyridyl]imidazolidine-2,4-dione (diastereoisomer 1); (5R)-5-ethyl-3-[6-[[3-methyl-3-(trifluoromethyl)-1H-isobenzofuran-5-yl]oxy]-3-pyridyl]imidazolidine-2,4-dione (diastereoisomer 2); (5R)-5-ethyl-3-(6-spiro[1H-isobenzofuran-3,1\u2032-cyclobutane]-5-yloxy-3-pyridyl)imidazolidine-2,4-dione; (5R)-5-ethyl-3-[2-[[3-methyl-3-(trifluoromethyl)-1H-isobenzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione (diastereoisomer 1); (5R)-5-ethyl-3-[2-[[3-methyl-3-(trifluoromethyl)-1H-isobenzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione (diastereoisomer 2); (5R)-5-ethyl-3-(2-spiro[1H-isobenzofuran-3,1\u2032-cyclobutane]-5-yloxypyrimidin-5-yl)imidazolidine-2,4-dione; (5R)-3-{4-[(3,3-dimethyl-1,3-dihydro-2-benzofuran-5-yl)oxy]phenyl}-5-ethyl-5-methyl-2,4-imidazolidinedione; (5R)-5-ethyl-5-methyl-3-[2-(7-methylspiro[2H-benzofuran-3,1\u2032-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione; (5R)-5-ethyl-5-methyl-3-{2-[(3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-2,4-imidazolidinedione; (5R)-3-{2-[(2,2-difluoro-7-methyl-1,3-benzodioxol-4-yl)oxy]-5-pyrimidinyl}-5-ethyl-5-methyl-2,4-imidazolidinedione; 5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1\u2032-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione; (5R)-5-ethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1\u2032-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione; (5R)-5-ethyl-3-[6-(7-methylspiro[2H-benzofuran-3,1\u2032-cyclopropane]-4-yl)oxy-3-pyridyl]imidazolidine-2,4-dione; (5R)-5-ethyl-3-{6-[(3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione; (5R)-5-ethyl-3-{2-[(3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-2,4-imidazolidinedione; (5R)-5-ethyl-5-methyl-3-[6-(7-methylspiro[2H-benzofuran-3,1\u2032-cyclopropane]-4-yl)oxy-3-pyridyl]imidazolidine-2,4-dione; 5,5-dimethyl-3-[6-(7-methylspiro[2H-benzofuran-3,1\u2032-cyclopropane]-4-yl)oxy-3-pyridyl]imidazolidine-2,4-dione; (5R)-5-ethyl-5-methyl-3-[2-({4-methyl-3-[(trifluoromethyl)oxy]phenyl}oxy)-5-pyrimidinyl]-2,4-imidazolidinedione; (5R)-5-ethyl-3-[2-({4-methyl-3-[(trifluoromethyl)oxy]phenyl}oxy)-5-pyrimidinyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-[2-({4-methyl-3-[(trifluoromethyl)oxy]phenyl}oxy)-5-pyrimidinyl]-2,4-imidazolidinedione; (5R)-5-ethyl-3-[6-({4-methyl-3-[(trifluoromethyl)oxy]phenyl}oxy)-3-pyridinyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-[6-({4-methyl-3-[(trifluoromethyl)oxy]phenyl}oxy)-3-pyridinyl]-2,4-imidazolidinedione; (5R)-5-ethyl-3-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)-2,4-imidazolidinedione; 5-methyl-4-{6-[(7-methylspiro[1-benzofuran-3,1\u2032-cyclopropan]-4-yl)oxy]pyridin-3-yl}-2,4-dihydro-3H-1,2,4-triazol-3-one; and 5-methyl-4-[6-(spiro[1-benzofuran-3,1\u2032-cyclopropan]-4-yloxy)pyridin-3-yl]-2,4-dihydro-3H-1,2,4-triazol-3-one; or a pharmaceutically acceptable salt and/or solvate thereof and/or derivative thereof.

Metadata:
- Claim Count in Document: 54.0
- Percentile: 94.0
- Lexical Diversity: 1.6
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14403011', '15730559', '14361510', '15208329', '14403048']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8322345458828262
- 35 USC 102 Novelty (BERT): 0.6454352275490717
- Combined Prediction Score: 0.8135546140494507
- Mean Citation Score: 527.578932
- Max Citation Score: 633.7182
- Similarity Product: 571.2133581897855

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test